Guggenheim analyst Seamus Fernandez has reiterated their bullish stance on IVA stock, giving a Buy rating yesterday.
Seamus Fernandez has given his Buy rating due to a combination of factors surrounding Inventiva’s recent developments. The company has successfully completed the enrollment for its NATiV3 trial, which is a significant milestone as it prepares for a comprehensive topline readout in the second half of 2026. This achievement not only advances their clinical program but also fulfills the criteria necessary to unlock additional financing, thereby strengthening their financial position.
Moreover, the trial’s main cohort exceeded its target enrollment, enhancing the statistical power of the study. This progress, coupled with the potential of their drug candidate Lani, which is anticipated to be a leading oral anti-fibrotic treatment, underscores the company’s promising outlook. These strategic advancements and the potential market impact of their pipeline contribute to Fernandez’s optimistic Buy rating.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.